PROGRAM CHAIR & FACULTY PRESENTER
Robert Gish, MD
Adjunct Professor of Medicine
University of Nevada Schools of Medicine Las Vegas
Reno Medical Director-Hepatitis B Foundation
Las Vegas, NV
The case-based enduring activity will cover the treatment and management of patients with hepatitis C infection.
This activity is intended for US-based nephrologists, hepatologists, gastroenterologists, infectious disease specialists, primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists, and case managers involved in the management of patients with HCV.
After completing the CME activity, learners should be better able to:
- Explain the rationale for HCV elimination efforts based on the disease course of infection and the associated negative health outcomes in untreated persons
- Use current screening recommendations and diagnostic guidance as part of the larger effort to eliminate HCV
- Develop interdisciplinary team-based strategies to eliminate HCV through reducing the stigma associated with infection, improving treatment adherence rates, and preventing further transmission
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care and treatment of patients with HCV. CNE Credits: 1.0 ANCC Contact Hour.
CNE ACCREDITATION STATEMENT:
Purpose: This program would be beneficial for nurses involved in the care of patients with HCV. Credits: 1.0 ANCC Contact Hour
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Dr. Gish reports the following disclosures:
Grants/Research Support: Gilead
Consultant and/or Advisor: Abbott, AbbVie, Access Biologicals, Alexion, Antios, Arena, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Eiger, Eisai, Enyo, eStudySite, Forty-Seven Inc, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Ionis Pharmaceuticals, Janssen, Laboratory for Advanced Medicine, Lilly, Merck, Salix, Shionogi, Trimaran, and Viking Therapeutics
Current Activity with Scientific or Clinical Advisory Boards: Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, Hatch BioFund, HepQuant, Intercept, Janssen, and Medimmune
Clinical Trials: eStudySite Advisor
Advisory Consultant: Diagnostic Companies: Biocollections, Fujifilm/Wako, and Quest
Data Safety Monitoring Board: Ionis, and Eiger
Responsible Medical Person: Viking Therapeutics Clinical Study FDA 1571 Application
Consulting Confidentiality Agreements: Abbvie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals Inc, Arrowhead, Arterys Inc Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Assoc, Dova Pharmaceuticals, DRG Abacus, Dynavax, Eiger, Enyo, Exelixis, Forty-Seven Inc, Fujifilm Wako Diagnostics, Gilead, HepQuant, HepaTx, Intellia, Intercept, Inotek, Iqvia, Janssen/J&J, KannaLife, Laboratory for Advanced Medicine, Labyrinth Holdings, Lilly, MedImmune, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, ProdigY Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi Inc, Spring Bank, Trimaran, and Viking Therapeutics
Speakers Bureau: AbbVie, Bayer, BMS, Dova, Eisai, Gilead Sciences Inc., Intercept, Salix, and Shionogi
Minor stock shareholder: RiboSciences, CoCrystal Stock Options: Eiger, HepQuant, and AngioCrine
Full details of all current and historical Research Grant Support: See current CV
Expert Testimony for Pharma (Intellectual Property): Janssen
CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
Staff, Planners, and Managers:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group has nothing to disclose.
Chris Drury, Medical Services for Med Learning Group, has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: July 23, 2020
EXPIRATION DATE: July 23, 2021
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.